"Low NR2F1 Expression May Predict Risk of Metastatic Breast Cancer" - Caroline Seymour
Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research. This research shows that the survival advantage in these patients is due to high levels of this protein. Tests using this protein marker could further improve curative treatment of breast cancer, sparing patients from unnecessary treatments,” said lead researcher, Julio Aguirre-Ghiso, PhD, director of Solid Tumor and Metastasis Research at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. "Identifying patients with disseminated disease that is not yet symptomatic and characterizing it for potential dormancy or metastatic recurrence is a gamer changer."
— Julio Aguirre-Ghiso, PhD, Director, Solid Tumor and Metastasis Research, Head and Neck Cancer Basic Research, Professor, Oncological Sciences, Otolaryngology, Medicine, Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai